CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER (CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER).
Amino acids provide substrates for protein synthesis and nitrogen balance; dextrose provides caloric support. Electrolytes maintain acid-base and fluid balance.
| Metabolism | Amino acids undergo hepatic deamination and transamination; dextrose is metabolized via glycolysis and oxidative phosphorylation; electrolytes are handled by renal and cellular mechanisms. |
| Excretion | Renal excretion of amino acids and dextrose metabolites; 100% eliminated via kidneys as urea, CO2, and water. Biliary/fecal negligible. |
| Half-life | Not applicable as a composite; individual amino acids: 0.5–2 h, dextrose: 1.5–2.5 h. Clinical context: continuous infusion reaches steady state within 4–6 h. |
| Protein binding | Minimal (<10%); amino acids are not significantly protein-bound; dextrose not bound. |
| Volume of Distribution | Approximately 0.2 L/kg (amino acids) to 0.25 L/kg (dextrose); reflects distribution into extracellular fluid. |
| Bioavailability | Intravenous: 100% bioavailable; not administered via other routes. |
| Onset of Action | Intravenous: immediate (seconds to minutes) upon infusion initiation for metabolic effects. |
| Duration of Action | Duration coincides with infusion time; metabolic effects persist for 30–60 min after cessation. |
Intravenous infusion. Dose individualized based on protein and calorie requirements. Typical adult dose: 500-2000 mL/day, providing 5% amino acids (50 g/L) and 15% dextrose (150 g/L). Infusion rate not to exceed 0.1 g/kg/hour of amino acids.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in patients with severe renal impairment (GFR <25 mL/min) unless dialyzing. In moderate impairment (GFR 25-50 mL/min), reduce protein intake to 0.6-0.8 g/kg/day. Monitor electrolytes and acid-base balance. |
| Liver impairment | Child-Pugh A/B: Use with caution; may require reduced protein intake (0.8-1.0 g/kg/day) to avoid precipitating hepatic encephalopathy. Child-Pugh C: Avoid high protein loads; consider branched-chain amino acid formulations. |
| Pediatric use | Dose based on weight: Protein 0.5-3.0 g/kg/day, dextrose 10-20 mg/kg/min. Administer via central line for concentrations >12.5% dextrose. Monitor serum glucose, electrolytes, and fluid balance. |
| Geriatric use | Start at low end of dosing range due to potential renal/hepatic impairment. Monitor for fluid overload, hyperglycemia, and electrolyte disturbances. Adjust protein and calories based on nutritional status and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER (CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER).
| Breastfeeding | Safety in breastfeeding has not been established. Excretion into human milk is unknown. M/P ratio: Not available. Dextrose and amino acids are endogenous substances and are likely present in breast milk at low levels. Use caution and consider the benefits of breastfeeding versus the potential for adverse effects. |
| Teratogenic Risk | CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER is a parenteral nutrition solution containing amino acids and dextrose. There are no adequate controlled studies in pregnant women. Dextrose at high doses may cause fetal hyperinsulinemia and hypoglycemia. Amino acid solutions are generally considered safe in pregnancy when used for maternal nutritional support. However, sulfites (present as a preservative in the container but labeled sulfite-free) may cause allergic reactions. Overall, the teratogenic risk is low but not well-studied. |
■ FDA Black Box Warning
Not for use in patients with intracranial or intraspinal hemorrhage, or those undergoing dialysis with dextrose-containing solutions.
| Serious Effects |
["Hypersensitivity to any component","Severe hyperglycemia or hyperosmolar coma","Severe electrolyte disorders","Intracranial or intraspinal hemorrhage (for solutions with dextrose)","Dialysis with dextrose-containing solutions (relative)"]
| Precautions | ["Risk of hyperglycemia, hyperosmolarity, and electrolyte disturbances","Monitor fluid balance, serum glucose, electrolytes, and renal function","Use with caution in renal impairment, cardiac failure, or patients on corticosteroids"] |
| Food/Dietary | No direct food interactions as it is an intravenous solution. However, concurrent oral intake should be managed to avoid hyperglycemia and electrolyte imbalances. |
Loading safety data…
| Fetal Monitoring | Monitor maternal electrolytes, renal function, liver function, blood glucose, acid-base balance, and fluid status. Fetal monitoring (e.g., ultrasound for growth) may be warranted in prolonged use, especially in pregnancy complicated by maternal malnutrition. |
| Fertility Effects | No specific studies on fertility. Parenteral nutrition is used for nutritional support and may improve fertility in malnourished women. No negative impact on fertility reported. |
| Clinical Pearls | Administer via central line due to high osmolarity (~1500 mOsm/L). Monitor serum glucose, electrolytes, and renal function closely. Do not use if patient has known egg allergy (contains egg lecithin). Use with caution in patients with hyperglycemia, lipemia, or severe hepatic disease. |
| Patient Advice | This solution provides nutrition through a vein; it is not for oral use. · Report any signs of infection at the IV site, such as redness, swelling, or warmth. · Tell your healthcare provider if you have diabetes, as blood sugar monitoring is essential. · Notify your doctor if you have allergies to eggs or soy. · This therapy requires regular lab tests to monitor your blood chemistry. |